Optical Coherence Tomography Angiography Equipment Market

USD 488.2 million in 2026 to USD 1172.7 million by 2036 at a 9.2% CAGR.

• As per Fact.MR analysis, the optical coherence tomography angiography equipment market was valued at USD 447.2 million.
• Demand will increase from USD 488.2 million in 2026 to USD 1172.7 million by 2036.
• The market is set to expand at 9.2% CAGR between 2026 and 2036.

Source: Fact.MR analysis. Updated Oct 12, 2026

What are the defining numbers behind Optical Coherence Tomography Angiography Equipment Market growth?

An absolute opportunity of USD 684.5 million is forecast between 2026 and 2036.

• Demand Drivers in the Market
  • Retina specialists use blood-flow images alongside structural scans to assess diabetic eye disease and conditions affecting the macula. The World Health Organization reported 3.9 million people with vision loss from diabetic retinopathy in its February 2026 fact sheet [1].
  • The U.S. Centers for Disease Control and Prevention reported in January 2026 that 40.1 million Americans had diabetes in 2023 [2]. Regular retinal care among people with diabetes creates opportunities for specialist imaging, including OCTA when doctors need to examine blood vessels.
• Key Segments Analyzed
  • By Product Type: Handheld Type leads with 58.3% share in 2026, reflecting the value placed on flexible patient placement in the defined product segmentation.
  • By Application: Hospitals account for 42.7% share in 2026, owing to their role in hard retinal reviews and specialist referrals.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, states, “Eye-care teams choose equipment based on how consistently they can capture useful blood-vessel images. Fact.MR's survey research will examine whether reliable scans and easy-to-read results matter more to buyers than having additional imaging modes.”
• Strategic Implications
  • Equipment manufacturers need to explain how motion correction and image processing improve OCTA image quality. These features help clinics capture clear, usable scans during busy working hours.
  • Hospital imaging teams can compare examination times before adding angiography to existing OCT services. The need for repeat scans also affects daily patient scheduling.
  • Clinic managers need to consider staff training when reviewing new imaging equipment. Continued software support also matters when comparing purchase prices and operating costs.
  • Equipment sellers must clearly explain the imaging features available in each device. Buyers need to know whether the system includes OCT angiography or only structural OCT and fundus photography.

Japan is set to record 11.9% CAGR through 2036, followed by Germany at 11.0%. The United Kingdom is estimated at 8.8%, while Brazil is forecast at 7.4%. The United States is set to post 6.6%.

How Is Multimodal Imaging Integration Improving the Clinical Value of OCT Angiography Equipment?

Multimodal imaging is becoming an important differentiator in OCT angiography because clinicians increasingly need structural and vascular information within the same workflow. Heidelberg Engineering combines OCTA with structural OCT, confocal scanning laser imaging and dye-based angiography on its SPECTRALIS platform [1]. ZEISS also integrates OCTA with fundus imaging and other retinal data through its multimodal workflow tools [2]. This integration allows specialists to correlate vascular abnormalities with structural retinal changes more efficiently. Equipment suppliers that combine several imaging functions within one platform can reduce workflow fragmentation, improve clinical interpretation and strengthen the value of OCTA systems for retinal assessment.

Handheld Type makes up 58.3% of Product Type; Hospitals make up 42.7% of Application in 2026.

Which Product Type dominates?

Handheld Type is projected to hold 58.3% share in 2026.

Source: Fact.MR analysis. Updated Oct 12, 2026

Handheld OCTA devices offer an option for patients who have difficulty using fixed chin-rest imaging systems. Their portable design allows clinical staff to position patients more easily during retinal examinations. Future sales assessments need clear evidence separating handheld OCT equipment from devices that specifically provide OCT angiography.

What leads the Application segment?

Hospitals are set to account for 42.7% share in 2026.

Source: Fact.MR analysis. Updated Oct 12, 2026

Hospital eye departments handle referred patients who require detailed retinal blood-vessel examinations and specialist imaging. Trained eye-care staff, suitable diagnostic equipment and regular follow-up services make OCTA useful in these departments. Future equipment purchases depend on daily patient needs, available imaging systems and the clinical requirements of each hospital.

Growing use of retinal blood-vessel imaging drives OCTA adoption, while equipment costs and image interpretation requirements limit wider use.

Driver Impact Analysis

Source: Fact.MR analysis. Updated Oct 12, 2026

Opportunity Impact Analysis

Source: Fact.MR analysis. Updated Oct 12, 2026

Restraints Impact Analysis

Source: Fact.MR analysis. Updated Oct 12, 2026

Source: Fact.MR analysis. Updated Oct 12, 2026

How is Japan developing OCT angiography equipment adoption?

11.9% CAGR, supported by diabetes monitoring and structured specialist eye care.

Japan's OCT angiography market has opportunities in hospital eye departments and research centers that carry out regular retinal blood-vessel examinations. The Ministry of Health, Labour and Welfare published its national health and nutrition survey findings in December 2025 [4]. Integrated OCT and angiography systems can fit into existing examination routines, making them useful for repeated imaging and patient follow-up.

What supports Germany’s adoption?

11.0% CAGR, supported by specialist retinal imaging and OCT equipment upgrades.

Upgrading existing eye-imaging equipment is an important business opportunity for OCT angiography suppliers in Germany. Retinal clinics and university hospitals use specialist imaging systems for selected patient follow-ups and research examinations. With approximately 83.5 million residents at the end of 2025, as reported by the Federal Statistical Office [5], Germany has an established population base for healthcare services. Equipment suppliers can focus on specialist eye-care centers seeking to add OCTA features to their current imaging systems.

How is the United Kingdom developing adoption?

8.8% CAGR, supported by organized eye-care pathways and specialist referrals.

NHS screening and specialist referrals shape the use of OCT angiography in the UK, particularly for patients needing detailed retinal blood-vessel examinations. NHS England published its 2025–2026 screening results reports through August 2026 [6]. Teaching hospitals can compare OCTA findings with existing structural OCT scans during selected clinical and research examinations. This creates opportunities for equipment suppliers serving hospitals that require both imaging methods.

What supports Brazil’s growth?

7.4% CAGR, supported by specialist retinal services and diabetes-care referrals.

Diabetes-related referrals create opportunities for OCT angiography in Brazil's major city hospitals, where specialists carry out detailed retinal examinations. The Ministry of Health reported that 81.3% of surveyed adults with diabetes in state capitals and the Federal District were taking diabetes medication in 2024 [7]. Eye hospitals can use established referral channels to identify patients who need further retinal blood-vessel imaging. Future equipment purchases will depend on the need for these specialist examinations.

How is the United States developing adoption?

6.6% CAGR, supported by established retinal care and clinical imaging upgrades.

Equipment upgrades in U.S. retinal clinics depend on whether OCT angiography provides useful blood-vessel images beyond standard structural OCT scans. ZEISS offers CIRRUS AngioPlex for examining retinal blood vessels without injected dye. Hospitals and private eye clinics can assess this system against their existing equipment and daily examination needs. Future purchases will reflect how well OCTA fits specialist imaging work and planned equipment upgrades.

Leading suppliers compete by offering imaging systems that combine structural OCT scans with retinal blood-flow assessment.

Carl Zeiss Meditec has a strong market presence through CIRRUS AngioPlex, highlighted in October 2025 for imaging retinal and choroidal blood vessels without injected dye [3]. Heidelberg Engineering offers the SPECTRALIS OCT Angiography Module with eye tracking for detailed retinal examinations. NIDEK supplies the Mirante SLO/OCT platform, while Canon provides OCT systems with angiography features. Topcon Corporation and Visionix (Optovue) are also among the key providers reviewed. Future competition will depend on scan quality, reliable image processing, ease of use, software support and equipment upgrades for hospitals and retinal clinics.

Key companies include Carl Zeiss Meditec AG; Heidelberg Engineering GmbH; Topcon Corporation; Visionix (Optovue); NIDEK CO., LTD.; and Canon Medical Systems Corporation.

• Carl Zeiss Meditec AG
• Heidelberg Engineering GmbH
• Topcon Corporation
• Visionix (Optovue)
• NIDEK CO., LTD.
• Canon Medical Systems Corporation

• [1] World Health Organization. (2026, February 10). Blindness and vision impairment.
• [2] Centers for Disease Control and Prevention. (2026, January 21). Diabetes data and statistics.
• [3] Carl Zeiss Meditec AG. (2025, October 7). ZEISS expands DORC portfolio and further strengthens digital footprint with improved workflow efficiency and digital visualization.
• [4] Ministry of Health, Labour and Welfare. (2025, December 2). [Results of the 2024 National Health and Nutrition Survey: Summary].
• [5] Statistisches Bundesamt (Destatis). (2026, June 16). Bevölkerung Deutschlands sinkt im Jahr 2025 um 0,1 % [Germany’s population declines by 0.1% in 2025].
• [6] NHS England. (2025, November 13; updated 2026, August 6). NHS population screening programmes: KPI reports 2025 to 2026.
• [7] Ministério da Saúde. (2026, July 7). Vigitel Brasil 2006–2024: Estimativas sobre frequência e distribuição sociodemográfica de fatores de risco e proteção para doenças crônicas nas capitais dos 26 estados brasileiros e no DF.

• The report explains the equipment boundary for OCT angiography and separates it from ordinary structural OCT and fundus imaging.
• Product analysis compares handheld and tabletop models without assuming every portable retinal scanner supports OCTA.
• Country analysis compares five supplied growth rates alongside referral and service-capacity considerations.
• Competition analysis separates verified angiography products from broader ophthalmic and medical-technology portfolios.

The market covers instruments that capture OCT angiography flow information for eye-care assessment. Structural OCT platforms belong inside the boundary only when the equipment configuration includes a functioning angiography capability.

What is included in the scope?

Included revenue relates to finished equipment and directly associated OCT angiography configurations. The classification covers handheld and tabletop product types and clinical use by hospitals or clinics.

What is excluded from the scope?

Standalone fundus cameras and ultrasound instruments are excluded when they cannot perform OCT angiography. Fluorescein angiography equipment is a separate category because it uses dye-based imaging.

How Was the Analysis Built?

The analysis draws on 120+ sources, 35+ company portfolios, 25+ countries, and more than 20 industry interviews.

• Primary Research: Primary research includes discussions with manufacturers, service providers, technology developers, distributors, end users, and subject-matter experts. These conversations examine purchasing priorities, product adoption, operational challenges, approval requirements, competitive positioning, and the factors that influence wider market acceptance.
• Desk Research: Desk research covers government statistics, regulatory publications, company filings, trade data, technical studies, industry associations, standards, public policy, and other authoritative sources. Every source used in the analysis is documented in the bibliography.
• Market Sizing and Forecasting: Market estimates combine historical performance, demand indicators, pricing and volume trends, segment shares, company participation, country-level growth, adoption patterns, investment activity, and barriers to market expansion.
• Data Validation and Update Cycle: Findings are validated by comparing primary interviews with public data, company activity, regulatory changes, trade patterns, and industry developments. Regular updates review new product launches, capacity changes, partnerships, approvals, and shifts in commercial adoption.